Table 2.
TRAEs of any grade occurring in ≥10% of patients.
| Any grade (%) | Grade ≥3 (%) | |
|---|---|---|
| Any TRAE* | 31 (100.0) | 23 (74.2) |
| Treatment-related SAEs | 7 (22.6) | 4 (12.9) |
| TRAEs leading to discontinuation | 1 (3.2) | 1 (3.2) |
| TRAE leading to dose delay or reduction | 21 (67.7) | 12 (38.7) |
| Leukopenia | 31 (100.0) | 16 (51.6) |
| Anemia | 31 (100.0) | 11 (35.5) |
| Neutropenia | 30 (96.8) | 23 (74.2) |
| Hypomagnesemia | 29 (93.5) | 1 (3.2) |
| Fatigue | 29 (93.5) | 0 |
| Anorexia | 28 (90.3) | 0 |
| Hypertriglyceridemia | 27 (87.1) | 1 (3.2) |
| Thrombocytopenia | 25 (80.7) | 10 (32.3) |
| Alanine Aminotransferase increased | 24 (77.4) | 2 (6.5) |
| Hyponatremia | 23 (74.2) | 0 |
| Nausea | 22 (71.0) | 0 |
| Aspartate Aminotransferase increased | 22 (71.0) | 1 (3.2) |
| Hypocalcemia | 20 (64.5) | 3 (9.7) |
| Constipation | 19 (61.3) | 0 |
| Hypercholesterolemia | 19 (61.3) | 0 |
| Hyperglycemia | 18 (58.1) | 0 |
| Alopecia | 18 (58.1) | 0 |
| Hyperuricemia | 18 (58.1) | 0 |
| Hypokalemia | 17 (54.8) | 3 (9.7) |
| Hypophosphatemia | 17 (54.8) | 0 |
| Proteinuria | 14 (45.2) | 0 |
| Weight loss | 14 (45.2) | 0 |
| Vomiting | 12 (38.7) | 0 |
| Hypercalcemia | 11 (35.5) | 0 |
| Creatinine increased | 9 (29.0) | 0 |
| Serum amylase increased | 9 (29.0) | 0 |
| Pain | 8 (25.8) | 1 (3.2) |
| Fever | 7 (22.6) | 0 |
| Insomnia | 7 (22.6) | 0 |
*TRAE, Treatment-related AEs.
All adverse events that occurred in at least 20% of patients are listed.